Market Movers rounded up the best reactions from investors and analysts on Eli Lilly . The experts, including Jim Cramer , discussed the drugmaker after it reported second-quarter revenue and earnings Tuesday that beat Wall Street estimates. The company also raised its full-year guidance as quarterly profit soared 85% from the same period last year.
Shares of Eli Lilly hit an all-time high during intraday trading, perhaps also getting a boost from a Novo Nordisk trial. The study found Novo Nordisk's obesity drug Wegovy, which shares some similarities with Lilly's Mounjaro, cut the risk of heart disease in participants by 20%. Eli Lilly's stock finished the day about 14.9% higher. LLY is currently held in Cramer's Charitable Trust portfolio.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut: